Current opinion in oncologyHumansGliomaIsocitrate DehydrogenaseBrain NeoplasmsAntineoplastic Agents
Open questions on vorasidenib.
Antoine Seyve, François Ducray
Published: 202510.1097/CCO.0000000000001193
Abstract
PURPOSE OF REVIEW: Vorasidenib has demonstrated efficacy in isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas that do not require immediate oncological treatment. Here, we summarize open questions regarding its long-term benefit, its optimal use…
Preview only. Read the full abstract at the source